Both anti-PD-1 and anti-CTLA4 antibodies exhibited comparable efficacy with anti-PD-L1 antibody in combination with imatinib, indicating that T cell immunity is more responsible for the effective elimination of CML LSCs than ADCC (Fig. 5i). The gene discussed is CTLA4; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.